Clinical Trials Logo

Adult Glioblastoma Multiforme clinical trials

View clinical trials related to Adult Glioblastoma Multiforme.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00895180 Completed - Clinical trials for Adult Glioblastoma Multiforme

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: July 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.